原研机构 |
在研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)早期临床1期 |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
多发性硬化症 | 临床1期 | 中国 | 2025-02-28 | |
重症肌无力 | 临床1期 | 中国 | 2025-02-28 | |
视神经脊髓炎 | 临床1期 | 中国 | 2025-02-28 | |
慢性炎症性脱髓鞘性多发性神经病 | 临床1期 | 中国 | 2025-02-28 | |
狼疮性肾炎 | 临床1期 | - | 2024-11-25 | |
B细胞淋巴瘤 | 临床1期 | - | 2023-12-20 | |
前体B细胞急性淋巴细胞白血病 | 临床1期 | - | 2023-12-20 | |
风湿性疾病 | 临床阶段不明 | 中国 | 2024-07-15 | |
难治性B细胞淋巴瘤 | 临床申请批准 | 中国 | 2025-04-17 |
N/A | 4 | 築鹽衊廠製遞顧鑰膚選(憲範廠遞遞鹽製糧艱夢) = The most commonly observed grade 3 or 4 adverse events within the first few weeks were neutropenia, lymphopenia, hepatic dysfunction, fever, and fatigue. Neutropenia and lymphopenia were attributed to the lymphodepletion conditioning regimen. All patients experienced only grade 1 cytokine release syndrome (CRS), manifesting as fever that persisted for 2–3 days. No patients developed immune effector cell-associated neurotoxicity syndrome (ICANS) or GVHD during treatment. 範顧獵獵顧網獵糧餘糧 (構憲膚鏇獵壓願窪遞膚 ) | 积极 | 2025-05-08 | |||
N/A | 3 | 憲構衊膚衊壓齋鏇襯憲(齋夢製築構襯鹽糧壓艱) = the significant improvement in the clinical response index scores for the two diseases, respectively, and supported by the observations of reversal of inflammation and fibrosis. 鏇鏇製蓋獵衊築構獵憲 (鏇簾範鹹選膚網鏇衊製 ) 更多 | 积极 | 2024-07-15 |